Industry News
Cellmid to buy Advangen Japan in $4m deal
Cellmid (ASX:CDY) will pay around $4m in cash and stock to acquire Advangen Japan and, with it, the hair growth technology platform behind Cellmid’s evolis line. [ + ]
Mystery disease solved by gene experts
A global team of researchers has identified the gene behind an Australian toddler’s paediatric brain disorder in a discovery that is paving the way for the diagnosis and treatment of other children with genetic diseases. [ + ]
Understanding honeybee hives
The unsustainable rate at which bee colonies are failing is driving work in understanding the conditions in which colonies flourish and those in which they fail. [ + ]
Concern over NSW indemnity insurance impact on clinical trials prompts survey
Members of AusBiotech are invited to participate in a survey to gauge the impact of the 2011 increase in the Clinical Trial Indemnity Insurance Compliance Requirement. [ + ]
New member for Prima board
Prima Biomed (ASX: PRR) has announced a new board member, Dr Russell Howard. [ + ]
Patrys study confirms PAT-SM6 effect in myeloma
A scientific article details the cancer cell killing effect that Patrys’ (ASX:PAB) anticancer antibody PAT-SM6 has in multiple myeloma. [ + ]
Royal Fellowship for Australian scientists
Three Fellows from the Australian Academy of Science have been elected to the prestigious Royal Society in the United Kingdom, the oldest scientific academy in the world. [ + ]
Iluvien launches in Germany
pSivida (ASX:PVA) licensee Alimera Sciences has followed up the launch of DME treatment Iluvien in the UK with the first commercial sale in Germany. [ + ]
Novogen appoints new CSO
Novogen (ASX:NRT) has announced two new executive appointments - a CSO, as well as a president and CEO of its new North American subsidiary. [ + ]
David Penington to headline AusMedtech Melbourne conference dinner
Emeritus Professor David Penington AC will deliver an insightful address about his experiences within the medical industry and how to translate medical research into products as part of the AusMedtech 2013 conference dinner on Wednesday 15 May 2013. [ + ]
Japan’s I’rom buys into IDT Australia
Japanese site management organisation (SMO) I’rom Holdings will pay $2m for a 19% stake in CMO IDT Australia, and the pair will combine their clinical trial site offerings in Australasia. [ + ]
Submission to reduce clinical trial insurance in NSW
Contributions are being sought for a submission to NSW Health to reduce clinical trial indemnity insurance in the state. [ + ]
Researchers banking on getting your thoughts
Menzies Research Institute Tasmania, an institute of the University of Tasmania, is calling for the public to voice their opinion on a Tasmanian biobank to inform an ongoing research project. [ + ]
Novogen finds new anticancer candidates
Novogen’s (ASX:NRT) anticancer program has identified two second-generation drug candidates, showing promise in pancreatic cancer and melanoma, and one will be fast-tracked to the clinic. [ + ]
Controlling lung inflammation in asthmatics
The biggest study of its type in the world is investigating a possible new treatment for asthma sufferers. [ + ]
